Biotech Pipeline Updates
Five Biotechnology Companies Announce Major Pipeline Advances and Upcoming Therapy Trials
Anonymous
Key Points
1
Cabaletta Bio reported that more than 90 patients treated with rese-cel had discontinued immunosuppressants and steroids in most cases, with no instances of immune effector cell–associated hemophagocytic syndrome (IEC-HS).
2
iBio said its Activin E antibody is the only antibody of its kind and could offer complete pathway blockade with dosing intervals of three to six months, while its IBIO-600 myostatin program has already advanced to first-patient dosing.
3
Editas plans to test EDIT-401 first in Australia in a Phase 1 study of heterozygous familial hypercholesterolemia patients who remain above target LDL levels despite standard treatment; the company expects safety data in the first quarter of 2027.
4
MiniMed said the Fit patch pump is designed with a 300-unit reservoir—about 50% more capacity than competing patch pumps—and up to seven days of wear; initial manufacturing capacity is expected to cover about 20,000 patients.
5
Celcuity said REVTORPYK’s triplet regimen of gedatolisib, palbociclib and fulvestrant produced median progression-free survival of 9.4 months, compared with two months for fulvestrant alone, with a hazard ratio of 0.24.
Five biotechnology companies are pushing forward with pipeline advances across oncology, metabolic disease, genetic disorders, and autoimmune conditions. Quartr reported that Cabaletta Bio achieved encouraging results in its nine-day CAR-T therapy, while iBio is developing long-acting antibody treatments and Editas Medicine plans human testing of an in vivo CRISPR therapy for cholesterol. MiniMed and Celcuity are also advancing therapies with potential regulatory filings and commercial launches planned within months.
Cabaletta's CAR-T Therapy Shows Strong Safety Profile
Cabaletta Bio reported that more than 90 patients treated with rese-cel have discontinued immunosuppressants and steroids in most cases, with no instances of serious immune complications. Quartr noted the company is planning pivotal studies in scleroderma and myositis, with potential regulatory filings possible by year-end. The nine-day autologous CD19 CAR-T therapy is designed to treat autoimmune diseases by targeting problematic immune cells.
iBio Pursues Long-Acting Obesity and Metabolic Treatments
iBio is developing Activin E antibody therapy, which the company claims is the only antibody of its kind and offers complete pathway blockade with dosing every three to six months. Quartr reported that iBio's myostatin program (IBIO-600) has already advanced to first-patient dosing. The therapies target durable weight loss, visceral-fat reduction, and muscle preservation for obesity and related cardiometabolic conditions.
Editas Launches CRISPR Trial for Hard-to-Treat High Cholesterol
Editas Medicine plans to begin human testing of EDIT-401, an in vivo CRISPR therapy designed to reduce LDL cholesterol, Lp(a), and ApoB in patients with familial hypercholesterolemia. Quartr reported the Phase 1 study will start first in Australia with patients who remain above target LDL levels despite standard treatment. The company expects safety data in the first quarter of 2027, marking a milestone for CRISPR-based cholesterol therapy.
MiniMed and Celcuity Push Diabetes and Cancer Advances Forward
MiniMed reported strong U.S. growth from successive diabetes-device launches and is preparing its Fit patch pump with a 300-unit reservoir—about 50% more capacity than competing pumps—designed to last up to seven days. Quartr stated initial manufacturing capacity is expected to cover about 20,000 patients. The company is also preparing its Vivera fully closed-loop system targeting greater insulin capacity and simpler management for Type 2 diabetes patients.
Celcuity is preparing to launch REVTORPYK for second-line metastatic breast cancer while pursuing broader indications. Quartr reported the company's triplet regimen of gedatolisib, palbociclib, and fulvestrant produced median progression-free survival of 9.4 months, compared with just two months for fulvestrant alone—a hazard ratio of 0.24. Clinical data support the triplet approach for additional breast and prostate-cancer indications.
Sentiment
Mostly PositiveNEGATIVENEUTRALPOSITIVE
Publishers
23
Articles
52
Reach
75
A
AnonymousAuthor
